Can a Once-Daily eye drop ease pain and swelling after cataract surgery?

NCT ID NCT06128369

Terminated Symptom relief Sponsor: Oculis Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial tests whether OCS-01, a dexamethasone eye drop, can reduce inflammation and pain after cataract surgery. About 117 adults scheduled for cataract removal will receive either the active drop or a placebo once daily. The study measures how well the drop clears eye inflammation and relieves pain in the weeks after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a dexamethasone eye drop formulation called OCS-01
What this could lead to: If effective, OCS-01 could offer a once-daily eye drop option to manage post-cataract surgery inflammation and pain.
What could go wrong: This is a Phase 3 trial, but results may not confirm benefit over placebo. Eye drops can cause side effects like increased eye pressure or delayed healing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATION EYE PAIN POSTOPERATIVE CATARACT

Contacts and locations

Locations

Oculis Investigative Site

Glendale, California, 91204, United States
Oculis Investigative Site

Inglewood, California, 90301, United States
Oculis Investigative Site

Newport Beach, California, 92663, United States
Oculis Investigative Site

Torrance, California, 90505, United States
Oculis Investigative Site

Tamarac, Florida, 33321, United States
Oculis Investigative Site

Morrow, Georgia, 30260, United States
Oculis Investigative Site

Northbrook, Illinois, 60062, United States
Oculis Investigative Site

Indianapolis, Indiana, 46240, United States
Oculis Investigative Site

Louisville, Kentucky, 40206, United States
Oculis Investigative Site

Woburn, Massachusetts, 01810, United States
Oculis Investigative Site

St Louis, Missouri, 63131, United States
Oculis Investigative Site

Washington, Missouri, 63090, United States
Oculis Investigative Site

Las Vegas, Nevada, 89145, United States
Oculis Investigative Site

Elizabeth City, North Carolina, 27909, United States
Oculis Investigative Site

Leland, North Carolina, 28451, United States
Oculis Investigative Site

Cincinnati, Ohio, 45242, United States
Oculis Investigative Site

Eugene, Oregon, 97401, United States
Oculis Investigative Site

Erie, Pennsylvania, 16507, United States
Oculis Investigative Site

Kingston, Pennsylvania, 18704, United States
Oculis Investigative Site

Nashville, Tennessee, 37212, United States
Oculis Investigative Site

Austin, Texas, 78731, United States
Oculis Investigative Site

Houston, Texas, 77008, United States
Oculis Investigative Site

San Antonio, Texas, 78229, United States
Oculis Investigative Site

Lynchburg, Virginia, 24502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.